UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Neurourology and urodynamics, 2014-01, Vol.33 (1), p.17-30

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)

BJU international, 2017-10, Vol.120 (4), p.562-575

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of candidate scaffolds for tissue engineering for stress urinary incontinence and pelvic organ prolapse repair

BJU international, 2013-09, Vol.112 (5), p.674-685

2013

Link zum Volltext

Verfügbarkeit prüfen

A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non‐neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)

BJU international, 2014-09, Vol.114 (3), p.427-433

2014

Link zum Volltext

Verfügbarkeit prüfen

Long‐term follow‐up of a multicentre randomised controlled trial comparing tension‐free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women

BJU international, 2015-06, Vol.115 (6), p.968-977

2015

Link zum Volltext

Verfügbarkeit prüfen

Oestradiol-releasing Biodegradable Mesh Stimulates Collagen Production and Angiogenesis: An Approach to Improving Biomaterial Integration in Pelvic Floor Repair

European urology focus, 2019-03, Vol.5 (2), p.280-289

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis

BJU international, 2017-11, Vol.120 (5), p.611-622

2017

Link zum Volltext

Verfügbarkeit prüfen

A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

Neurourology and urodynamics, 2013-11, Vol.32 (8), p.1116-1122

2013

Link zum Volltext

Verfügbarkeit prüfen

Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review

Neurourology and urodynamics, 2012-01, Vol.31 (1), p.13-21

2012

Link zum Volltext

Verfügbarkeit prüfen

Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder"

Neurourology and urodynamics, 2014-07, Vol.33 (S3), p.S6-S13

Chapple, Christopher

2014

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

International journal of clinical practice (Esher), 2017-05, Vol.71 (5), p.e12944-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

BJU international, 2005-05, Vol.95 (7), p.993-1001

2005

Link zum Volltext

Verfügbarkeit prüfen

Comparison of fesoterodine and tolterodine in patients with overactive bladder

BJU international, 2008-11, Vol.102 (9), p.1128-1132

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tolterodine extended‐release in men with overactive bladder symptoms treated with an α‐blocker: effect of baseline prostate‐specific antigen concentration

BJU international, 2010-11, Vol.106 (9), p.1332-1338

2010

Link zum Volltext

Verfügbarkeit prüfen

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

BJU international, 2005-01, Vol.95 (1), p.81-85

2005

Link zum Volltext

Verfügbarkeit prüfen

It is a great pleasure to introduce to you the fourth edition of this year

Neurourology and urodynamics, 2015-04, Vol.34 (4), p.299-299

Chapple, Christopher

2015

Link zum Volltext

Verfügbarkeit prüfen

Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder

Expert opinion on pharmacotherapy, 2006-12, Vol.7 (17), p.2421-2434

Chapple, Christopher R

2006

Link zum Volltext

Verfügbarkeit prüfen

Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder

Neurourology and urodynamics, 2014-07, Vol.33 (S3), p.S1-S1

Chapple, Christopher

2014

Link zum Volltext

Verfügbarkeit prüfen

A mixed methods study to assess the feasibility of a randomised controlled trial of invasive urodynamic testing versus clinical assessment and non-invasive tests prior to surgery for stress urinary incontinence in women: the INVESTIGATE-I study

Trials, 2015-09, Vol.16 (1), p.400-400, Article 400

2015

Link zum Volltext

Verfügbarkeit prüfen

A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome

BJU international, 2007-02, Vol.99 (2), p.355-359

2007

Link zum Volltext

Verfügbarkeit prüfen

Lower urinary tract symptoms in men

BMJ (British Medical Journal), 2007-01, Vol.334 (7583), p.2-2

2007

Link zum Volltext

Verfügbarkeit prüfen

Which drugs are best for overactive bladder? From patients’ expectations to physicians’ decisions

International journal of clinical practice (Esher), 2021-04, Vol.75 (4), p.e13870-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity

Neurourology and urodynamics, 2013-11, Vol.32 (8), p.1109-1115

2013

Link zum Volltext

Verfügbarkeit prüfen

The use of laser as a therapeutic modality as compared to TURP for the small prostate ≤40 mL: a collaborative review

Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2019-12, Vol.71 (6), p.569

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study

European urology focus, 2024-01, Vol.10 (1), p.90-97

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(33)
Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Urology & Nephrology
(25)
Female
(22)
Male
(19)
Adult
(18)
Middle Aged
(16)
Urinary Bladder, Overactive - Drug Therapy
(16)
Aged
(14)
Overactive Bladder
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Nephrology. Urinary Tract Diseases
(11)
Quality Of Life
(11)
Double-Blind Method
(10)
Urinary Incontinence
(10)
Urinary System Involvement In Other Diseases. Miscellaneous
(10)
Urinary Tract. Prostate Gland
(10)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)

Comparison of candidate scaffolds for tissue engineering for stress urinary incontinence and pelvic organ prolapse repair

A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non‐neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)

Long‐term follow‐up of a multicentre randomised controlled trial comparing tension‐free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women

Oestradiol-releasing Biodegradable Mesh Stimulates Collagen Production and Angiogenesis: An Approach to Improving Biomaterial Integration in Pelvic Floor Repair

Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis

A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review

Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder"

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

Comparison of fesoterodine and tolterodine in patients with overactive bladder

Efficacy and safety of tolterodine extended‐release in men with overactive bladder symptoms treated with an α‐blocker: effect of baseline prostate‐specific antigen concentration

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

It is a great pleasure to introduce to you the fourth edition of this year

Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder

Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder

A mixed methods study to assess the feasibility of a randomised controlled trial of invasive urodynamic testing versus clinical assessment and non-invasive tests prior to surgery for stress urinary incontinence in women: the INVESTIGATE-I study

A prospective, randomized, double‐blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome

Lower urinary tract symptoms in men

Which drugs are best for overactive bladder? From patients’ expectations to physicians’ decisions

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity

The use of laser as a therapeutic modality as compared to TURP for the small prostate ≤40 mL: a collaborative review

Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study

Aktive Filter

Suchergebnisse filtern